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a  b  s  t  r  a  c  t
Arginine  kinase  is not  only  absent  from  mammalian  hosts  but is  critical  to the  survival  of trypanosomes
under  stressful  conditions  and consequently  its  inhibition  may  lead  to an  effective  treatment  for  try-
panosomiasis.  The  His-tagged  enzyme  was cloned  from  Trypanosoma  brucei  genomic  DNA,  expressed  in
Escherichia  coli BL21  DE3  cells  and  puriﬁed  on  a Ni-afﬁnity  column  and  by FPLC  on  a  Superdex  200  HR.
The  enzyme  had  a  speciﬁc  activity  of  2.92 mol min−1 mg  protein−1, molecular  mass  of 40  kDa,  temper-
ature  and pH  optima  of  30 ◦C and 7.8,  and  K and  V as  2.94  mM  and  0.161  mol  ml−1 min−1 (arginineeywords:
rypanosomiasis
rginine kinase
ilver, gold nanoparticles
inetic analysis
m max
substrate).  The  interaction  of the  enzyme  with  silver  and  gold  nanoparticles  showed  a  non-competitive
inhibition  with, respectively,  75% and 62%  decrease  in activity;  Ki values  ranged  from  1.5 nM  (Ag) to
3.1  nM  (Au).  A  mechanism  for this  inhibition  was  by  interaction  with  Cys271 positioned  3.3 A˚ from  the
reactive  NH1 of  substrate  arginine.  This  cysteine  controls  electrophilic  and  nucleophilic  character  of  the
guanidinium  group  that  is crucial  for enzymatic  phosphoryl  transfer  between  ADP  and  ATP.echanism
. Introduction
Trypanosomes are responsible for the economically important
eterinary infections and severe human diseases. In Africa, Try-
anosoma brucei causes sleeping sickness also known as the African
rypanosomiasis, while in America, Trypanosoma cruzi causes Cha-
as disease [1–3]. Infection by the T. brucei is fatal if untreated. It
s however unfortunate that the current treatments are beset with
everal shortcomings including limited efﬁcacy, unwanted toxic-
ty and emergence of resistant strains of trypanosomes. These and
ther factors highlight the need for innovative strategies to combat
he disease. The absence of effective anti-trypanosomal therapies
oupled with unsuccessful efforts at vaccine development occa-
ioned by the phenomenon of antigenic variation has stimulated
he numerous research investigations directed at understanding
he molecular biology and biochemistry of trypanosomes. Among
he biomedical target molecules which have been identiﬁed as
ossible drug targets in trypanosomatids is arginine kinase (AK),
 phosphotransferase enzyme responsible for the reversible for-
ation of phosphoarginine using l-arginine and ATP as substrates
Fig. 1) [4]. Phospho-arginine can act as an emergency reservoir,
ot only of ATP but also for inorganic phosphate [5–7].
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el.: +27 46 6038085; fax: +27 46 6223984.
E-mail address: C.Whiteley@ru.ac.za (C.G. Whiteley).
141-8130/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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The enzyme AK is absent in humans [8], a fact that makes it
an attractive target choice for trypanocide development. These
researchers demonstrated an increased activity of AK in try-
panosomes when linked to oxidative stress and its inhibition, in
any way possible, would be lethal to the parasite supporting the
importance of AK to the survival of the trypanosomes. During the
parasite life-cycle the trypanosomes are constantly exposed to the
pro-oxidants in the blood of mammalian host, and consequently
either the absence of AK or its decrease in activity would present
serious consequences to the growth and survival of the parasites. In
light of this, compounds that selectively inhibit AK are desirable and
should become candidates for early development of trypanocides.
Metal nanoparticles, especially silver and gold, with their
increased solubility, have been reported to possess interesting
properties including anti-microbial activity [9,10], and to cause
changes in enzyme activities [11–13].
Engineering nanoparticles that are capable of selective binding
to enzymes, is a new research direction with exciting prospects in
biomedical applications and there are two fundamental approaches
used – either a direct covalent or non-covalent link [14,15]. In the
former, there is multiple non-speciﬁc binding of the nanoparticle
to cysteine side chains leading to a loss of enzyme activity, usu-
ally with conformational changes to protein structure. With the
second, non-covalent method, either ‘naked’ or fully functionalised
nanoparticles interact with enzymes under normal protein–protein
interactions through the evolution of a loosely attached protein
‘corona’ around the nanoparticles. The ‘naked’ nanoparticles tend
to irreversibly bind and deform an initial layer of biomolecules that
O.S. Adeyemi, C.G. Whiteley / International Journal of Biological Macromolecules 62 (2013) 450– 456 451
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orm the ﬁrst ‘corona’ layer, while functionalised nanoparticles,
hich already have an irreversible bound initial layer, act similarly
y binding available biomolecules [14–16]. The binding between
anoparticles and the enzyme changes the structure of the latter
nd as the particle gets smaller not only does its interaction with the
rotein change but the composition of the protein itself changes.
onsequently the ‘nanoparticle-enzyme corona’ has totally differ-
nt biological properties in comparison to a native enzyme.
The nanoscale size of these metal nanoparticles allows their
nique and remarkable properties to be exploited within the
anomedical fraternity [17–21] and to resolve several medical chal-
enges in both infectious (malaria) and neurodegenerative diseases
Alzheimer). It is against this backdrop that the present study
ought to investigate the interaction of silver and/or gold nanopar-
icles with a recombinant form of AK obtained from T. brucei (TbAK).
. Materials and methods
.1. Materials
Genomic DNA of T. brucei (strain: 927/4GUTat 10.1) was a
ift from Professor Ullman, Department of Biochemistry & Bio-
hysics, Oregon Health & Science University, Portland, Oregon, USA.
nzymes and PCR reagents were provided by Thermo Fischer Sci-
ntiﬁc, USA. A Bioﬂux kit was obtained from Separation Scientiﬁc
South Africa). Oligonucleotides and primers were from the Inte-
rated DNA Technology (IDT) USA. The clone JET PCR kit, pSMART
nd pET-28b (+) as well as the BL21 DE3 and JM 109 strain of E. coli
ere obtained from Fermentas Life Sciences (USA). Absorbance
pectroscopy was performed with a Synergy Mx  (Monochromator
ulti-Mode Microplate Reader, Biotek Instruments, Inc., USA). All
ther reagents were of analytical grade and obtained from Sigma,
SA or from domestic suppliers unless otherwise stated.
.2. Cloning of TbAK from genomic DNA [22]
The speciﬁc primers of TbAK including the forward (CAT ATG
GC TTC GGA TCA TCA AAA CCC) with NdeI restriction site under-
ined and reverse (CTC GAG CTG TTC CAC GTA CCT GC) with XhoI
estriction site underlined were used to amplify the ORF of the
bAK gene. The PCR reaction was carried out with ampliﬁcation
onditions as follows: 98 ◦C at 3 min, 98 ◦C at 30 s, 62 ◦C for 30 s,
2 ◦C for 1 min, 72 ◦C, and held at 4 ◦C in a Biorad T100 ther-
al  cycler. The 1000 bp product by PCR, excised and gel puriﬁed
sing a Bioﬂux kit was phosphorylated and blunt ligated into a
SMART vector using a T4 DNA ligase and then transformed into
M 109 cells. The plasmid containing TbAK was gel puriﬁed using
he Bioﬂux kit and sequenced. This product showed 100% iden-
ity with the Trypanosoma brucei expressed product (Accession for arginine kinase.
number – XP 826998.1) and a high identity with other related
guanidino kinases. The plasmid was  double digested and a frag-
ment between NdeI and XhoI restriction sites containing the TbAK
gene was excised from the plasmid and subcloned into pET-28b (+)
expression vector previously treated with NdeI and XhoI. This plas-
mid  transcribes under the control of T7 promoter and includes a
polyhistidine tag.
2.3. Expression and puriﬁcation of TbAK
A method previously described [23] was adopted with slight
modiﬁcation. The recombinant plasmid pET-28b (+) containing
the TbAK gene was  transformed into BL21 DE3 cells. The trans-
formed cells were grown overnight, at 37 ◦C, in 50 ml  LB culture
medium containing kanamycin after which an aliquot (5.0 ml)
was transferred into a 2 L ﬂask containing auto-media culture
(500 ml). This was grown at 20 ◦C, at 150 rpm for 36 h. Cells
were then harvested (6000 × g, 10 min) washed twice with Tris
buffered saline (Tris–HCl, 50 mM;  NaCl, 150 mM;  pH 7.5) and lysed
(freeze-thawed [−80 ◦C/4 ◦C; 2 cycles]) in lysis buffer [NaH2PO4
buffer (50 mM,  pH 7.6) containing NaCl (300 mM),  glycerol (10%),
Tween (0.25%), imidazole (10 mM),  mercaptoethanol (10 mM),
phenylmethylsulphonylﬂuoride (1 mM)]. The lysed cells were cen-
trifuged (2700 × g, 30 min) and the supernatant centrifuged further
(100,000 × g, 90 min) after which the supernatant (150 ml)  was
loaded onto a Ni-nitrilotriacetic acid afﬁnity column. The column
was washed with the same lysis buffer until a steady zero-baseline
was obtained and then the fusion protein was  eluted with increas-
ing amounts of imidazole (0-500 mM)  in Hepes buffer (10 mM,
pH 7.5). The eluted protein was concentrated using vivaspin (GE
Healthcare, Sweden) and the concentrated protein further puriﬁed
by FPLC on a Superdex 200 HR 10/30 with Hepes buffer (25 mM,
pH 7.6) containing glycerol (15%), EDTA (0.1 M),  and KCL (1 M)  at
a ﬂow rate (1 ml  min−1). Proteins were resolved by SDS-PAGE in
order to conﬁrm purity of fractions before pooling. All puriﬁcation
procedures were carried out at 4 ◦C.
2.4. SDS-PAGE
The effectiveness of the puriﬁcation process was determined
by SDS-PAGE [24] on samples exhibiting TbAK activity. Samples
from each puriﬁcation step (20 l) and a standard molecular weight
marker (10-170 kDa) were electrophoresed on 12% SDS-PAGE at
200 V. The gels were stained with Coomassie Brilliant Blue R-250,
then destained in methanol:acetic acid:water (3:1:6 v/v/v). The
molecular weight of the partially puriﬁed TbAK was determined
using a standard curve of log molecular weight versus distance
migrated.
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.5. Kinetic, pH, temperature and stability proﬁles
The activity of TbAK was assayed using a published proto-
ol [25] with slight modiﬁcation. Brieﬂy, enzyme extract (20 l)
as incubated (5 min, 30 ◦C) with l-arginine (10 mM),  ATP (5 mM),
ercaptoethanol (10 mM),  MgSO4 (200 mM)  in Tris–HCl buffer
100 mM,  pH 8.6) in a ﬁnal volume of 170 l. The reaction was
topped by the addition of trichloroacetic acid (180 l, 2.5%), heated
100 ◦C, 2 min) then allowed to cool. This mixture was  treated with
scorbic acid/ammonium molybdate (9%, 100 l), left for colour
evelopment (5 min), and the absorbance read at 700 nm.  The
inetic properties (Km and Vmax) were determined by varying the
ubstrates of either arginine (0.5–5 mM)  (ﬁxed ATP concentration
 5 mM)  or ATP (1–5 mM)  (ﬁxed arginine concentration – 10 mM)
nd determining the activity of TbAK at each substrate concen-
ration. One unit of TbAK activity is the amount of enzyme that
atalyses the formation of 1 mol  inorganic phosphate per minute
er ml.
To determine the pH optimum, the enzyme extract (20 l) was
ssayed in different buffers [sodium acetate (pH 3–5.5, 50 mM);
epes (pH 6-7, 50 mM);  Tris–HCl buffer (pH 7.5-10, 50 mM)]  under
he standard assay conditions. The temperature optimum of the
artially puriﬁed enzyme was determined in Tris–HCl buffer (pH
.6, 50 mM)  over a range of 20-70 ◦C. The reaction was started by
ddition of enzyme suspension (20 l) at the different tempera-
ures. The temperature stability of TbAK was determined at the
ptimum temperature and pH and the enzyme activity at time zero
as considered to be 100% relative activity and aliquots (20 l)
ere removed at 15 min  intervals and analysed for activity for a
aximum period of 4 h.
.6. Protein determination
The protein concentration for all experiments was  routinely
etermined, in triplicate, according to published procedures [26].
n a 96-well titre plate was placed extract (5 l) followed by Brad-
ord reagent (245 l). The mixture was incubated (22 ◦C, 10 min),
he absorbance of the solution measured at 595 nm and the con-
entration of the unknown sample was determined using a BSA
tandard curve.
.7. Gold and silver nanoparticles
.7.1. Synthesis
The silver/gold nanoparticles (Ag/Au-Nps) were synthesised
ased on established protocols [27,28]. Either AgNO3 (5 ml,
00 mM)  or AuCl3 (5 ml,  50 mM)  was added to tannic acid [20 ml,
% (w/v)] with stirring followed by polyvinylpyrrolidone (0.2 g)
nd then an adjustment of pH to 8.0 by potassium carbonate
150 mM).  The solution turned pale yellow (Ag-NPs) or wine red
Au-NPs). The Ag/Au-Nps were ﬁltered using the 0.22 M ﬁlter
nd characterised by UV/vis spectrophotometry (Biotek Epoch,
SA), inductively coupled plasma optical emission spectrometry
ICP-OES, Cambridge, United Kingdom), energy dispersive X-ray
pectroscopy (EDX) and transmission electron microscopy (TEM,
rno, Czech Republic).
able 1
rotein puriﬁcation table for TbAK.
Fraction Vol. (ml) Protein
(mg  ml−1)
Total protein
(mg)
Ac
(U
Crude 200 2.29 458 2.0
Ni-afﬁnity chromatography 150 0.45 67.5 0.8
FPLCSuperdex 200 HR 30 0.22 6.6 0.6Biological Macromolecules 62 (2013) 450– 456
2.7.2. Characterisation
2.7.2.1. UV/vis spectroscopy. UV/vis absorption spectra
(250–700 nm)  of the nanoparticles were obtained to evalu-
ate the plasmon bands associated with the silver and/or gold
nanoparticles.
2.7.2.2. Inductively coupled plasma optical emission spectroscopy (ICP
OES). Nanoparticles (250 l) were dissolved in aqua regia [1:3
nitric to hydrochloric acid, 350 l (Au); 500 l (Ag)] and digested
with hydrogen peroxide (1.0 ml,  60 ◦C, 1 h). Metal quantiﬁcation
was carried out using an inductively coupled optical emission spec-
trophotometer after suitable standard curves were constructed
with varying concentrations of respective metal salt standards
(Sigma Aldrich).
2.7.2.3. Transmission electron microscopy (TEM). Samples for TEM
analysis were prepared by placing a drop of the nanoparticle sample
onto carbon coated copper grids, removing excess sample after a
minute using blotting paper and the grids air-dried before analysis.
Duplicate samples were prepared and negatively stained using 1%
uranyl acetate. Mean particle size and standard deviations were
determined by the analysis of 200 particles using the computer
software “Scandium”.
2.7.2.4. Energy dispersive X-ray spectroscopy (EDX). Freeze dried
samples were placed on graphite tape which was in turn placed
on an aluminium stub. Elemental analysis was  performed with
a TESCAN SEM with an EDX scanner (INCAPentalFeTx3, Oxford
Instruments) operating at 20 keV.
2.8. Kinetic analysis of interaction of Ag/Au nanoparticles with
TbAK
The analysis was  performed in the same way as that described
above for TbAK activity with the same variation in substrate of
either arginine (0.5–5 mM)  (ﬁxed ATP concentration – 5 mM)  or
ATP (1–5 mM)  (ﬁxed arginine concentration – 10 mM)  and either
silver or gold nanoparticles (0 nM;  2 nM;  5 nM)  in a total volume of
170 l. The TbAK activity was assayed, over a 5 min  period, at each
substrate concentration.
2.9. Statistical analyses
All analyses were carried out in triplicate and values reported as
the means with standard deviation, p < 0.05 versus controls. Where
necessary analysis of variance was  conducted using Statistica for
Windows, version 8 (Statsoft Inc.) and Microsoft Excel 2010.
3. Results
3.1. Cloning of TbAK gene
Following speciﬁc ampliﬁcation of the TbAK gene from using
speciﬁc primers, a PCR product of approximately 1000 bp was
obtained. Subsequently, the nucleotide sequencing result revealed
absence of mutation and a 100% identity to the Trypanosoma brucei
expressed sequence (Accession number – XP 826998.1).
tivity
 ml−1)
Total
activity (U)
Speciﬁc activity
(U mg−1)
Fold purity % Yield
2 404.0 0.88 1.0 100
8 132 1.96 1.72 32.7
4 19.2 2.92 3.32 4.8
O.S. Adeyemi, C.G. Whiteley / International Journal of 
Fig. 2. SDS-PAGE for TbAK: lane Y is fraction collected following puriﬁcation of
the His-tag eluate on a Superdex 200 HR 10/30 fast protein liquid chromatography
(FPLC) system; lane Z represents the protein marker. Arrow within the gel represents
the puriﬁed TbAK.
Fig. 3. Transmission electron microscopy images (TEM) for: (A) Au nanoparticles; (B) A
plasmon resonance band for: (C) Au nanoparticles (540 nm); (D) Ag nanoparticles (420 nmBiological Macromolecules 62 (2013) 450– 456 453
3.2. Expression and puriﬁcation of TbAK
The recombinant TbAK gene was  expressed in E. coli BL21 DE3
harbouring the vector pET-28b (+) TbAK. Approximately 9.45 g of
cells were harvested from 2 L of auto-media, lysed and puriﬁed on
Ni-nitriloacetic acid afﬁnity column. This was  further puriﬁed on a
Superdex 200 HR 10/30 FPLC column yielding a near homogeneous
protein in a ﬁnal yield of only 4.8% (Table 1). The molecular weight
of the fusion protein was  estimated to be around 40 kD as revealed
on SDS-PAGE (Fig. 2). The speciﬁc activity of the recombinant TbAK
was 2.92 mol  min−1 mg  protein−1. The optimum temperature and
pH for the recombinant TbAK are 30 ◦C and 7.8, respectively (data
not shown).
3.3. Silver/gold nanoparticles: synthesis and characterisation
The UV/vis spectrophotometry with maximal absorbance wave-
length at 420 and 540 nm,  respectively, indicated the plasmon
resonance absorbance of the Ag/Au nanoparticles [27,28] (Fig. 3).
The TEM analysis of the synthesised nanoparticles revealed
them to be spherical in shapes with sizes ranging from 4 to
9 nm and 7 to 22 nm,  respectively, for Ag and Au nanoparticles
(Fig. 3). After ICP-OES analysis the concentration of the metal
nanoparticles was 30.8 and 76.6 M for Ag and Au nanoparticles,
respectively.
3.4. Kinetic analysisA study into the effect of substrate concentration on the kinetic
activity of TbAK was investigated by measuring enzyme activity
over a range of arginine concentrations (0–5 mM).  A typical increase
in substrate concentration resulted in a proportional increase in
g nanoparticles. Scale bar = 200 nm.  Visible absorbance spectrum illustrating the
).
454 O.S. Adeyemi, C.G. Whiteley / International Journal of Biological Macromolecules 62 (2013) 450– 456
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Fig. 4. (a) Hanes–Woolf plots for the interaction of gold (A) and silver (B) nanoparticles with arginine kinase (ex Trypanosoma brucei)  in the presence of different concentrations
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oncentrations of ATP.
ctivity as shown by the Hanes–Woolf plot (Fig. 4) and with argi-
ine as substrate, the Vmax and Km were 0.161 mol ml−1 min−1 and
.94 mM,  respectively. With a total amount of enzyme of 340 nmol
he turnover number (kcat) and the catalytic efﬁciency were calcu-
ated using Eqs. (1) and (2) and were found to be 0.0079 s−1 and
.68 × 10−6 s−1M−1, respectively.
cat = VmaxEt (1)
atalytic efﬁciency = kcat
Km
(2)
The interaction of the silver and gold nanoparticles with TbAK
as determined by including the particles at a concentration
f 2 and 5 nM with either arginine, between 0.5 and 5 mM
oncentration at ﬁxed levels of ATP (5 mM),  or ATP, between
 and 5 mM concentration at ﬁxed levels of arginine (10 mM).
he results indicated that with respect to arginine as a vari-
ble substrate, for each type of particle the Vmax decreased
Fig. 4a), while the Km virtually remained unchanged. At 5 nM Au
anoparticle the Vmax decreased from 0.161 mol  min−1 ml−1 to
.067 mol  min−1 ml−1 – a 62% decrease. At 2 nM Au nanoparti-
le the Vmaxapp was 0.082.5 mol  min−1 ml−1 – an approximate
ecrease of enzyme activity of 50%. The decrease is more effec-
ive with Ag nanoparticle. At 5 nM Ag nanoparticle the Vmaxrticles with arginine kinase (ex Trypanosome brucei)  in the presence of different
decreased from 0.161 mol  min−1 ml−1 to 0.041 mol min−1 ml−1
– a 75% decrease. At 2 nM Ag nanoparticle the Vmaxapp was
0.078 mol  min−1 ml−1 – an approximate decrease of enzyme
activity of 48%. The inhibitor constant (Ki) calculated from Eq. (3)
indicated the binding afﬁnity of TbAK for the nanoparticles.
Ki =
[np · Vappmax]
[Vmax − Vappmax]
(3)
where np is the concentration of nanoparticle; Vmaxapp is the
apparent maximum velocity in the presence of nanoparticle.
Results indicated that Ag nanoparticles inhibited TbAK the most
as reﬂected by its relatively low Ki value of 1.59 nM;  Ki values for
Au nanoparticle was  estimated at 3.1 nM.
With ATP as the variable substrate (Fig. 4b) Vmax and Km are
0.208 mol  min−1 ml−1 and 0.06 mM,  respectively, and there was
over 90% inhibition of the enzyme with Ag nanoparticles (Fig. 5) and
close to 95% inhibition with Au nanoparticle; respective Ki values
are 4.7 nM and 7.2 nM.
4. DiscussionSince arginine kinase from T. brucei is absent in mammalian
hosts [8] yet is critical for trypanosome survival under stressful
conditions it was  clear that studies targeted at selective inhibition
of TbAK had high clinical implications in combating the disease.
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The current study has investigated the interaction between
etal nanoparticles (Ag and Au) and TbAK and evidence pre-
ented shows decreased enzyme activity by 75–50%. For the
ase of Au nanoparticles the maximum decrease in Vmax was
2% (from 0.161 mol  min−1 ml−1 to 0.067 mol  min−1 ml−1)
hile with Ag nanoparticles this decrease was over 75% (from
.161 mol  min−1 ml−1 to 0.041 mol  min−1 ml−1). With Km val-
es remaining fairly constant it pointed towards a non-competitive
nhibition with respect to both arginine and ATP substrates suggest-
ng the particles bind to sites on the enzyme other than the active
ites.
Although a thorough computational molecular docking of the
g/Au nanoparticles with TbAK is currently being undertaken and
ill be reported elsewhere, the mechanism of binding and interac-
ion is as yet unclear. Earlier studies by our group has inferred that
uch nanoparticles have strong afﬁnity to the thiol ( SH) group of
ysteine residues in enzymes and were responsible for the change
n enzyme conformation and change in activity [12,13,20,21].
hough it may  be regarded as being speculative we  offer a possible
echanism.
As far as we were aware no crystallographic structure for argi-
ine kinase from T brucei had been deposited in the Protein Data
ank. On the other hand that for T. cruzi (TcAK) had been reported
ig. 6. Tentative mechanism for the interaction of silver/gold nanoparticle with argi-
ine kinase from Trypanosoma cruzi TcAK [PDB ID: 2J1Q] through Cys271, interfering
ith N1 of the arginine substrate. The four arginine residues (Arg124, Arg126, Arg280,
nd  Arg309) and Glu314 are all involved to enhance the enzymatic rate through the
lignment of substrate [31]. The interatomic distance between the thiolate atom of
ys271 and NH1 of the arginine substrate is 3.3 A˚. Nitrate not shown.Biological Macromolecules 62 (2013) 450– 456 455
[29] with 82% analogy [2] to T. brucei.  The analysis of the primary
structure of TcAK (PDB ID: 2J1Q) reveals that the active site for
TbAK consists of four arginine residues (Arg124, Arg126, Arg280, and
Arg309) and a glutamic acid residue (Glu314) all of which enhance
the enzymatic rate through the alignment of substrate [30]. Con-
trary to this work, however, it is seen that the thiolate sulphur atom
from Cys271 is 3.3 A˚ from the reactive NH1 of the arginine substrate
and 4.82 A˚ from the unreactive N (Fig. 6); it is the NH1 that becomes
covalently phosphorylated. These workers imply that Cys271 is not
absolutely essential for TbAK catalysis and does not participate in
a substrate-induced conformational change of the enzyme [29].
It is possible [31] that the electronegative thiolate would induce
overall positive charge to the reactive NH1 of the arginine sub-
strate disrupting the resonance of the guanidinium group and
increasing the nucleophilicity of this reactive NH1 towards attack
on the -phosphoryl group of ATP. With the ATP forming reac-
tion (reverse scenario) a proton disposition from the guanidinium
group towards the thiolate should enhance any phosphoryl transfer
to ADP. Our suggestion that Ag/Au nanoparticles interact with
this thiolate atom supports our ﬁndings for inhibition of the
enzyme and that since the cysteine is not directly involved at the
active site lends credence for a non-competitive mechanism for
inhibition.
Reiterating, at this stage that it may  be considered speculation
to propose a tentative mechanism it is probable that the following
scenarios may  occur. Not only do the noble metallic nanoparti-
cles, especially Au and Ag, have catalytic properties [32,33] but
it is a well known fact that they have a high propensity for
sulphur. Consequently, based upon other ﬁndings from our lab-
oratories [20,21], the Au/Ag nanoparticles would then associate
with the sulphur atom of Cys271 decreasing its electronegativity.
At the same time, since the NH1 of the arginine substrate is only
3.3 A˚ away from this cysteine, there would be disruption of res-
onance of the guanidinium group and an enhancement of proton
migration. This would, in turn, decrease the nucleophilicity of the
NH1 towards attack on the -phosphoryl group of ATP. For the
enzymatic formation of ATP, a blocking of the Cys271 thiolate by
nanoparticles would prevent its acceptance of a proton from the
guanidinium group decreasing the overall phosphoryl transfer to
ADP.
5. Conclusion
To our knowledge, this is the ﬁrst report demonstrating the
inhibitory potentials by the Ag/Au nanoparticles on the activity of
TbAK with Ki values in the nM range: 1.59 nM (Ag); 3.1 nM (Au) in
the presence of arginine as substrate and 4.7 nM (Ag);7.2 nM (Au)
in the presence of ATP as substrate. Overall the decrease in enzyme
activity was  75% in the presence of Ag nanoparticles and 62% with
Au nanoparticles. The mechanism of inhibition was  consistent with
non-competitive interactions with either, or both substrates (ATP;
arginine). Cys271 is juxtapositioned 3.3 A˚ from the reactive NH1
of the substrate arginine and we  propose that in line with other
reported evidence, when the nanoparticles interact with the thio-
late group of Cys271 they disrupt, not only its electronegativity but
also the resonance of the guanidinium group decreasing nucleophi-
lic potential of the NH1 towards attack on the -phosphoryl group.
Any interference of the thiolate by nanoparticles would also pre-
vent proton transfer from the guanidinium group decreasing the
overall phosphoryl transfer to ADP.Conﬂict of interest
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